At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NKTX Nkarta
Post-Mkt 09-09 16:22:59 EDT
2.91
-0.32
-9.91%
盘后2.89
-0.02-0.69%
16:13 EDT
High3.20Low2.86Vol781.38K
Open3.19D1 Closing3.23Amplitude10.53%
Mkt Cap208.20MTradable Cap175.89MTotal Shares71.55M
T/O2.37MT/O Rate1.29%Tradable Shares60.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nkarta to Present Initial Phase 1/2 Autoimmune Data for CAR-NK Therapy Nkx019 at ACR Convergence 2026
Reuters  ·  09-08 19:01
Nkarta to Present Initial Phase 1/2 Autoimmune Data for CAR-NK Therapy Nkx019 at ACR Convergence 2026
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)
TIPRANKS  ·  08-18
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)
Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives
Reuters  ·  08-14
Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives
NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
Reuters  ·  08-14
NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track
Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises
Reuters  ·  08-14
Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises
Ovid Therapeutics Q2 Revenue Beats Estimates
Reuters  ·  08-13
Ovid Therapeutics Q2 Revenue Beats Estimates
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Reuters  ·  08-12
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Pliant Therapeutics Q2 Net Loss Narrows on Operating Expenses Decline, Reduced Headcount
Reuters  ·  08-12
Pliant Therapeutics Q2 Net Loss Narrows on Operating Expenses Decline, Reduced Headcount
Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs
Reuters  ·  08-11
Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs
Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs
Reuters  ·  08-11
Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs
Shattuck Labs Q2 Net Loss Widens as R&D Spending Rises
Reuters  ·  08-11
Shattuck Labs Q2 Net Loss Widens as R&D Spending Rises
Nkarta, Inc. : H.c. Wainwright Cuts Target Price to $14 from $16
THOMSON REUTERS  ·  08-11
Nkarta, Inc. : H.c. Wainwright Cuts Target Price to $14 from $16
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)
TIPRANKS  ·  08-11
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)
Nkarta, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-11
Nkarta, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Benzinga Earnings  ·  08-11
Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate
Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029
Reuters  ·  08-11
Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029
Nkarta Q2 FY26 Net Loss Widens to $40.4 Million
Reuters  ·  08-11
Nkarta Q2 FY26 Net Loss Widens to $40.4 Million
Nkarta Q2 EPS USD -0.54
Reuters  ·  08-11
Nkarta Q2 EPS USD -0.54
Nkarta Q2 Cash & Investments USD 243.2 Million
THOMSON REUTERS  ·  08-11
Nkarta Q2 Cash & Investments USD 243.2 Million
Nkarta, - Expects Cash to Fund Operations into 2029
THOMSON REUTERS  ·  08-11
Nkarta, - Expects Cash to Fund Operations into 2029

Introduction

Company Name.
Nkarta
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Issue price:
--